Semcon gets order for bio-tech factory in the US
Semcon gets order for bio-tech factory in the US Semcon has further underpinned its position in the Medical focus area through its strategic partnership with Pharmadule Emtunga, concerning the planning and design of module-based bio-tech factories. Semcon has received an order for preparing designs, on 14 000 engineering hours. The planning assignment has arisen through Aventis, a pharmaceutical company, commissioning Pharmadule Emtunga to build a bio-tech factory in Pennsylvania, USA. Pharmadule Emtunga AB is a world-leading supplier of modular facilities. The modules are primarily used to construct pharmaceutical factories, offshore industry housing, and mobile telephone system units. Over the past half year, Pharmadule has seen progressively rising, worldwide demand for its facilities. Pharmadule Emtunga will build a bio-tech factory of around 3000 sq. meters in Pennsylvania for Aventis and Semcon will prepare the modular designs. Semcon will carry out the assignment in Göteborg, Sweden, close to Pharmadule Emtunga's production facility in Arendal. "Projects like this, which look at the overall picture and involve a lot of different expertise, are perfect for Semcom," says David Hellström, area manager at Semcon. "We have a flexible organization, so we can quickly put together a project organization that's close to the customer." Earlier this year, Semcom was also involved in preparations for constructing another modular pharmaceutical factory, where Vitrolife in Denver, Colorado was the end customer. "Working with Semcom has meant that we can handle larger projects with shorter lead times," says Tomas Wängberg, CEO of Pharmadule Emtunga. "We also see opportunities for continuing this attractive cooperation." "The pharmaceutical industry is global, and most of our projects in this area are international," says Hans Johansson, Semcon's CEO. "We are currently running projects in the US, Austria, Poland, Denmark, and Germany." * This is detailed information concerning the order mentionned in Semcon's interim report published on the 22 of August. Contact: Tomas Wängberg, CEO, Pharmadule, tomas.wangberg@pharmadule.se, tel.: +46 512-324 00 Hans Johansson, CEO, Semcon AB, tel.: +46 70-591 43 34 David Hellström, area manager, Semcon Sweden AB, tel.: +46 70-544 96 95 ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2001/09/04/20010904BIT00260/bit0002.doc http://www.waymaker.net/bitonline/2001/09/04/20010904BIT00260/bit0002.pdf